BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Thursday, December 18, 2025
Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 30, 1999

View Archived Issues

Phase I clinical trial of Ushercell completed

Read More

Company Profile: HepaVec

Read More

DWH-146e and rolipram synergistically block inflammation in murine model of peritonitis

Read More

Cortecs changes identity to reflect new strategy

Read More

Neuronal nicotinic acetylcholine receptor ligands in early development at Pfizer

Read More

Anticoagulant, antithrombotic compounds with heterocyclic structure

Read More

Helix describes novel antimicrobial therapeutics particularly for Candida and Pseudomonas infections

Read More

Sigma-Tau prepares new esters useful as cationic lipids for intracellular (gene) delivery

Read More

(Anti)-estrogenic compounds designed at HMR for osteoporosis

Read More

GW-395058 assessed for pharmacokinetics and effects on platelets in monkeys

Read More

Korean farnesyltransferase inhibitor predicted to have favorable PK profile in humans

Read More

IDEC-131: pharmacokinetics and pharmacodynamics in monkeys given repeated infusions

Read More

GTI-2501 associated with complete tumor regression in animal models of kidney and breast cancer

Read More

First toxicity, pharmacokinetic data for JAK3 inhibitors presented at recent scientific meeting

Read More

Therion receives NIH funding for development of novel AIDS vaccines

Read More

Ligand applies for E.U. marketing approval of Targretin as CTCL therapy

Read More

Sindan and Pfizer team up to develop new multitargeted antifolate

Read More

Interneuron licenses U.S. rights to urinary incontinence treatment

Read More

Vertex and Taisho collaborate on caspase inhibitor development

Read More

3-DP investigators study role of MMP in tumor angiogenesis

Read More

Potential lack of drug interactions for the SERMs droloxifene and lasofoxifene

Read More

Vanguard to jump on the M&A bandwagon?

Read More

Neurocrine Biosciences reports positive phase II results with new insomnia agent

Read More

Deracoxib may be suitable for once-daily dosing according to studies in dogs

Read More

New lobucavir prodrug and its quantitative determination along with active compound in plasma

Read More

Lundbeck and Novo Nordisk join forces to discover innovative drug candidates

Read More

FDA approves twice-daily dosing of Viracept

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Dec. 18, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Dec. 18, 2025.
  • Left: Anthony Fauci. Right: Transmission electron micrograph of HIV-1 virus particles

    HIV research is close to a cure but far from ending the pandemic

    BioWorld
    Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
  • GLP-1 capsule

    Maintenance, man: Lilly’s phase III weight trial hits goals

    BioWorld
    Eli Lilly and Co. took another step toward adding a way for patients to hang onto their weight loss when the firm disclosed positive top-line data from the phase...
  • Insilico CEO Alex Zhavoronkov and the automated lab’s humanoid that runs all preclinical tests in the Hong Kong lab.

    AI drug developer Insilico to raise $292 million in Hong Kong IPO

    BioWorld
    Insilico Medicine Inc. plans to raise HK$2.27 billion (US$292 million) in its IPO on the Hong Kong Securities Exchange to advance its clinical pipeline and invest...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing